세계의 인플루엔자 치료제 시장 : 약제 클래스별, 딜리버리 형태별, 인플루엔자 유형별, 유통 채널별, 최종 사용자별 예측(2025-2030년)

The Influenza Medication Market was valued at USD 3.44 billion in 2023, expected to reach USD 3.60 billion in 2024, and is projected to grow at a CAGR of 5.00%, to USD 4.84 billion by 2030.

The influenza medication market is defined by the substances used to prevent, reduce, or treat flu symptoms, which can include antiviral drugs and various supportive treatments. The necessity of these medications arises from the seasonal prevalence and potential severity of influenza outbreaks, which pose significant public health challenges. The application spans from individual preventive measures to broader public health strategies employed by healthcare institutions. End-use scope includes hospitals, pharmacies, and online drug stores, catering to both prescription and over-the-counter needs. Key factors influencing market growth include increasing global awareness of flu prevention, advancements in drug formulations, and growing governmental health initiatives. Opportunities arise from the potential to expand into emerging markets where access is currently limited, as well as developing more efficient delivery mechanisms like inhalers or faster-acting formulations. However, limitations and challenges such as high competition from generic drugs, stringent regulatory landscapes, and vaccine hesitancy can restrict market growth. Continuous innovation in vaccine technology, particularly in the development of universal influenza vaccines and personalized medicine approaches, offers promising avenues for growth. Additionally, digital technology integration, such as AI-driven flu prediction models, can enhance distribution strategies and market penetration efficiency. These innovations could offer consumer-centric solutions that meet the evolving health needs. Furthermore, economic pressures can affect consumer purchasing power, highlighting the importance of cost-effective alternatives and access strategies. The market is competitive, with large pharmaceutical companies dominating, but there's room for new entrants that can offer novel, efficient solutions. Tailoring products to demographic-specific needs and expanding awareness through education campaigns could provide competitive advantages. For businesses seeking growth, focusing on collaborations with healthcare providers and leveraging AI for market insight and prediction can offer significant benefits in navigating and thriving within this dynamic market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Medication Market

The Influenza Medication Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of influenza across the globe
  • Government initiatives and awareness programs for influenza management
  • Growing inclination towards personalized medicine approaches
• Market Restraints
  • Associated high cost of novel influenza drug development
• Market Opportunities
  • Surge in influenza drug approvals from regulatory authorities
  • Favorable investments for development of new formulations and delivery methods
• Market Challenges
  • Adverse health outcomes of influenza medications

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Medication Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Medication Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Medication Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Medication Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Medication Market

A detailed market share analysis in the Influenza Medication Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Medication Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Medication Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Medication Market

A strategic analysis of the Influenza Medication Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Medication Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Cocrystal Pharma, Inc., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Qiagen N.V., Sandoz International GmbH, Sanofi SA, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Influenza Medication Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Baloxavir, Oseltamivir, Peramivir, and Zanamivir.
• Based on Delivery Form, market is studied across Inhalers, Intravenous, Liquid/Syrup, and Tablets/Capsules.
• Based on Influenza Type, market is studied across Type A, Type B, Type C, and Type D.
• Based on Distribution Channel, market is studied across Offline and Online.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Facilities, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of influenza across the globe
    • 5.1.1.2. Government initiatives and awareness programs for influenza management
    • 5.1.1.3. Growing inclination towards personalized medicine approaches
  • 5.1.2. Restraints
    • 5.1.2.1. Associated high cost of novel influenza drug development
  • 5.1.3. Opportunities
    • 5.1.3.1. Surge in influenza drug approvals from regulatory authorities
    • 5.1.3.2. Favorable investments for development of new formulations and delivery methods
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse health outcomes of influenza medications
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Influenza Medication Market, by Drug Class

• 6.1. Introduction
• 6.2. Baloxavir
• 6.3. Oseltamivir
• 6.4. Peramivir
• 6.5. Zanamivir

7. Influenza Medication Market, by Delivery Form

• 7.1. Introduction
• 7.2. Inhalers
• 7.3. Intravenous
• 7.4. Liquid/Syrup
• 7.5. Tablets/Capsules

8. Influenza Medication Market, by Influenza Type

• 8.1. Introduction
• 8.2. Type A
• 8.3. Type B
• 8.4. Type C
• 8.5. Type D

9. Influenza Medication Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Offline
• 9.3. Online

10. Influenza Medication Market, by End-User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Homecare Facilities
• 10.4. Hospitals & Clinics

11. Americas Influenza Medication Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Influenza Medication Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Influenza Medication Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. AstraZeneca PLC
• 4. Bio-Rad Laboratories, Inc.
• 5. Bristol-Myers Squibb Company
• 6. Cocrystal Pharma, Inc.
• 7. CSL Limited
• 8. Daiichi Sankyo Company, Limited
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche AG
• 11. GlaxoSmithKline PLC
• 12. Lupin Limited
• 13. Merck & Co., Inc.
• 14. NATCO Pharma Limited
• 15. Novartis AG
• 16. Pfizer Inc.
• 17. Qiagen N.V.
• 18. Sandoz International GmbH
• 19. Sanofi SA
• 20. Shionogi & Co., Ltd.
• 21. Sun Pharmaceutical Industries Ltd.
• 22. Takeda Pharmaceutical Company Limited
• 23. Teva Pharmaceutical Industries Ltd.
• 24. Viatris Inc.
• 25. Zydus Pharmaceuticals, Inc.